Servier, Nerviano in deal for preclinical TTK inhibitors

Servier (Neuilly-sur-Seine, France) paid Nerviano Medical Sciences s.r.l. (Nerviano, Italy) EUR 8 million ($10.6 million) in exchange for an option to license worldwide rights to develop and commercialize preclinical Nerviano compounds that inhibit TTK protein kinase (TTK; MPS1), a cell cycle regulator. Servier said preclinical data suggest TTK may "represent an attractive therapeutic target in a poor prognosis associated subgroup of breast cancer." ...